Tesidolumab (LFG316) for treatment of C5-variant patients with paroxysmal nocturnal hemoglobinuria

Affiliations

• ¹ Department of Hematology and Oncology, Osaka University Graduate School of Medicine, Suita. junnishi@bldon.med.osaka-u.ac.jp.
• ² Department of Hematology and Oncology, Tokai University, Isehara.
• ³ Department of Hematology, Endocrinology and Metabolism, Niigata University Medical and Dental Hospital, Niigata.
• ⁴ Department of Cardiology and Hematology, Fukushima Medical University, Fukushima.
• ⁵ Department of Hematology, Tokyo Medical University, Shinjuku-ku, Tokyo.
• ⁶ Department of Internal Medicine, Hematology and Oncology, Masaryk University Hospital and Faculty of Medicine, Brno, Czech Republic.
• ⁷ Hematology, Oncology and Transfusion Medicine Center, Vilnius University Hospital Santaros Klinikos and Institute of Clinical Medicine, Vilnius University, Vilnius.
• ⁸ Novartis Institutes for BioMedical Research, Basel, Switzerland, Cambridge, USA, and Novartis Pharma KK, Toranomon Minato-ku, Tokyo.
• ⁹ Department of Hematology and Oncology, Osaka University Graduate School of Medicine, Suita, Japan; Sumitomo Hospital, Osaka.